Ipsen S.A. Overview
Pro stress-test →Ipsen is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. The company achieved total sales growth of 10.9% at constant exchange rates in 2025, supported by solid 7.5% growth in Q4. With a market cap of $13.4B and strong momentum driven by recent strategic acquisitions and pipeline breakthroughs, Ipsen is positioned as a specialty pharma leader.
Strategic Profile
Pro stress-test →Oncology remains a cornerstone of Ipsen's business, delivering 4.1% growth and accounting for 69% of total 2025 sales. In December 2025, Ipsen expanded its immuno-oncology portfolio with the acquisition of ImCheck Therapeutics, developing next-generation immuno-oncology therapies including IPN60340 (ICT01), a first-in-class monoclonal antibody targeting BTN3A. The company leverages internal and external innovation alongside nearly 100 years of development experience across global hubs.
Competitive Landscape
Pro stress-test →Ipsen competes in the specialty pharma and oncology space against larger multinational pharma (Roche, Novartis, Bristol Myers Squibb) and emerging immuno-oncology specialists. Its differentiation lies in focused therapeutic areas, specialized pipeline (particularly rare disease and neuroscience), and recent acquisitions strengthening oncology capabilities.
Industry Context
Ipsen S.A. operates in Biopharmaceuticals - Specialty Pharma (Oncology, Rare Disease, Neuroscience focus).
Key facts
Founded: 1929 · Headquarters: Paris, France · Revenue: $4.08B · Market cap: $13.4B